First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Felip et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69def0c840ea065679559ce8 — DOI: https://doi.org/10.1007/s00280-022-04414-6

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex· 2001 · 349 citations
2. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)· 2017 · 873 citations
3. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer· 2016 · 161 citations
4. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis· 2017 · 468 citations
5. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models· 2022 · 13 citations